On February 14, 2024, Seagen requested director review of the PTAB’s January 16th Final Written Decision (“FWD”) in PGR2021-00030 finding antibody-drug conjugate claims in U.S. Patent No. 10,808,039 (the “’039 patent”) unpatentable. See PTAB Issues Final Written Decision Finding Seagen’s Adcetris® Patent Claims Unpatentable.

In support of the request to vacate the FWD, Seagen argued that because the ’039 patent claims priority to a parent application filed in 2004 (before the effective date of the AIA) and none of the subsequent continuation applications in the family introduced new matter, the ’039 patent was not eligible for PGR and thus the PTAB lacked jurisdiction. While Seagen raised the issue of PGR eligibility prior to PGR Institution, the merits were not addressed directly in the FWD.

We continue to monitor this case and will provide updates as they become available. For more information about this and other biosimilar patent disputes, visit BiologicsHQ.



The authors would like to thank April Breyer Menon for her contributions to this article.



    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates